Caption Management, LLC Mirati Therapeutics, Inc. Transaction History

Caption Management, LLC

$6.26 Billion
Q1 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $604,656 - $898,272	-14,400 Reduced 28.24%	36,600 $2.15 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $55,600 - $90,700	2,000 Added 4.08%	51,000 $2.22 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $1.77 Million - $2.43 Million	49,000 New	49,000 $1.77 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $3.04 Million - $7.26 Million	73,661 Added 99.22%	147,900 $6.7 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $4.42 Million - $6.44 Million	74,239 New	74,239 $5.18 Million

Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $45,795 - $91,185	604 Added 5.81%	11,000 $904,000
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $9.97 Million - $14.4 Million	-75,515 Reduced 87.9%	10,396 $1.53 Million
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $9.11 Million - $12.2 Million	68,911 Added 405.36%	85,911 $15.2 Million
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $2.29 Million - $2.86 Million	-15,900 Reduced 48.33%	17,000 $2.75 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $4.11 Million - $5.73 Million	25,875 Added 368.33%	32,900 $5.64 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $256,849 - $380,827	1,585 Added 29.14%	7,025 $1.54 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $2.14 Million - $3.15 Million	-18,860 Reduced 77.61%	5,440 $903,000
Q4 2019 Feb 13, 2020	SELL	$70.76 - $128.86 $1.11 Million - $2.02 Million	-15,700 Reduced 39.25%	24,300 $3.13 Million
Q1 2019 May 14, 2019	BUY	$43.65 - $78.95 $1.75 Million - $3.16 Million	40,000 New	40,000 $2.93 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.

Account